Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease-The McGill experience

Journal of Crohn's and Colitis

Volumn 8, Issue 11, 2014, Pages 1516-1522

  Kopylov, U ^a   Afif, W ^a   Cohen, A ^b   Bitton, A ^a   Wild, G ^a   Bessissow, T ^a   Wyse, J ^b   Al Taweel, T ^a   Szilagyi, A ^b   Seidman, E ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Biologics; Crohn's disease; TNF alpha inhibitors; Ustekinumab

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; CORTICOSTEROID; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; NATALIZUMAB; PREDNISONE; TACROLIMUS; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; CROHN DISEASE; DRUG DOSE ESCALATION; DRUG TREATMENT FAILURE; DRUG USE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; MALE; OBSERVATIONAL STUDY; OPEN STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TERTIARY CARE CENTER; TREATMENT RESPONSE; UNIVERSITY HOSPITAL; ADOLESCENT; ANTAGONISTS AND INHIBITORS; CANADA; DRUG RESISTANCE; MIDDLE AGED; RETREATMENT; SUBCUTANEOUS DRUG ADMINISTRATION; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; CANADA; CROHN DISEASE; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; RETREATMENT; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84927796919     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2014.06.005     Document Type: Article

References (16)

1. Sandborn W.J. The future of inflammatory bowel disease therapy: where do we go from here?. Dig. Dis. 2012, 30(Suppl. 3):140-144.
2. Yanai H., Hanauer S.B. Assessing response and loss of response to biological therapies in IBD. Am. J. Gastroenterol. 2011, 106:685-698.
3. Sandborn W.J., Gasink C., Gao L.L., et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N. Engl. J. Med. 2012, 367:1519-1528.
4. Scherl E.J., Kumar S., Warren R.U. Review of the safety and efficacy of ustekinumab. Ther. Adv. Gastroenterol. 2010, 3:321-328.
5. Strober W., Fuss I.J. Proinflammatory Cytokines in the Pathogenesis of Inflammatory Bowel Diseases. Gastroenterology 2011, 140. 1756-U82.
6. Berrebi D., Besnard M., Fromont-Hankard G., et al. Interleukin-12 expression is focally enhanced in the gastric mucosa of pediatric patients with Crohn's disease. Am. J. Pathol. 1998, 152:667-672.
7. Duerr R.H., Taylor K.D., Brant S.R., et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006, 314:1461-1463.
8. Iwakura Y., Ishigame H. The IL-23/IL-17 axis in inflammation. J. Clin. Investig. 2006, 116:1218-1222.
9. Neurath M.F. IL-23: a master regulator in Crohn disease. Nat. Med. 2007, 13:26-28.
10. Yen D., Cheung J., Scheerens H., et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin. Investig. 2006, 116:1310-1316.
11. Wang K., Zhang H., Kugathasan S., et al. Diverse Genome-wide Association Studies Associate the IL12/IL23 Pathway with Crohn Disease. Am. J. Hum. Genet. 2009, 84:399-405.
12. Sandborn W.J., Feagan B.G., Fedorak R.N., et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008, 135:1130-1141.
13. Leonardi C.L., Kimball A.B., Papp K.A., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008, 371:1665-1674.
14. Papp K.A., Langley R.G., Lebwohl M., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008, 371:1675-1684.
15. Lebwohl M., Yeilding N., Szapary P., et al. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. J. Am. Acad. Dermatol. 2010, 63:571-579.
16. Toussirot E., Michel F., Bereau M., Binda D. Ustekinumab in chronic immune-mediated diseases: a review of long term safety and patient improvement. Patient prefer. adherence 2013, 7:369-377.